Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Imaxio Acquires Orphan Drug Indicated for a Congenital Metabolic Disease

Published: Tuesday, January 22, 2013
Last Updated: Tuesday, January 22, 2013
Bookmark and Share
This acquisition strengthens Imaxio’s pharmaceutical range, which now includes two products sold in France and will finance the development of its vaccine candidates.

Imaxio has announces the acquisition of Trolovol(R) (D-penicillamine), a drug for human usage indicated for an orphan disease affecting around 1,200 patients in France. This product previously belonged to D&A Pharma and the transaction was facilitated by CMC Consulting. The financial terms of the deal have not been disclosed.
 
This purchase will allow Imaxio to generate almost EUR 500,000 of additional revenue in 2013, representing an increase of 20 per cent in its turnover compared to 2012. This revenue will be re-invested in research and development activities relating to its proprietary technology for reengineering antigens, known as IMX313. This technology is used to significantly increase immunogenicity and thus the efficacy of vaccines in which it is used.
 
This acquisition also fits in with Imaxio’s strategy of consolidating its pharmaceutical range. The company currently distributes Spirolept(R), a human vaccine indicated for preventing a professional infectious disease, which became part of Imaxio’s portfolio in 2009 following the acquisition of the company Axcell Biotechnologies. In 2012, sales of Spirolept(R) totalled almost EUR two million and generated a turnover of EUR 2.5 million.
 
“We are delighted to have finalised this transaction, which is a perfect fit for our external growth strategy,” said Alexandre Le Vert, managing director of Imaxio. “With the revenue generated by the sales of Trolovol(R), Imaxio will have the additional means necessary to advance in the clinical field, in particular with regard to its highly promising IMX313 technology for vaccines. Over the next three years, there are plans for Phase I/IIa clinical trials in indications for tuberculosis, influenza and staphylococcus aureus infections."

In the medium term, Imaxio plans to acquire further new products and to licence its IMX313 immunogenic technology for new indications in human and animal healthcare.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Imaxio Signs an Option for a License Agreement with DKFZ
Imaxio’s pro-immunogenic technology will be tested to enhance the efficacy of a candidate vaccine for the human papillomavirus.
Friday, October 17, 2014
Imaxio Announces the First Human Clinical Trial Using its Pro-Immunogenic Technology IMX313, in Tuberculosis
IMX313 has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial.
Monday, September 16, 2013
Imaxio Announces the First Human Clinical Trial Using IMX313 in Tuberculosis
IMX313, Imaxio’s antigen re-engineering technology, has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial managed by the Jenner Institute at Oxford University.
Wednesday, September 04, 2013
Bellerophon Project Awarded EUR 5.5 Million by EU to Develop Staphylococcus Aureus Vaccine
A consortium has been awarded a major FP7 grant to support development and phase I clinical trial of an S. aureus vaccine.
Wednesday, July 03, 2013
Bellerophon Project Awarded EUR 5.5 Million by EU to Develop S. aureus Vaccine
A consortium comprising Imaxio, the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems has been awarded a major FP7 grant to support development and phase I clinical trial of an S. aureus vaccine.
Tuesday, July 02, 2013
Imaxio Signs an Option for a License Agreement with Merial
This option agreement confirms the potential of Imaxio’s antigen re-engineering technology to improve human and animal health vaccines.
Tuesday, December 18, 2012
Imaxio Boosts Genomics Capacity with New Automated Equipment
Investment means larger scale, faster high throughput sequencing for Imaxio customers.
Friday, June 29, 2012
Imaxio Closes EUR 2.9 Million Funding Round
Funding will enable the clinical development of its IMX313 carrier protein platform for vaccines, and update the marketing authorization application it filed in France.
Wednesday, April 18, 2012
Scientific News
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism and Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Genetic Variant May Help Explain Why Labradors Are Prone To Obesity
A genetic variation associated with obesity and appetite in Labrador retrievers – the UK and US’s favourite dog breed – has been identified by scientists at the University of Cambridge. The finding may explain why Labrador retrievers are more likely to become obese than dogs of other breeds.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Flowering Regulation Mechanism Discovered
Monash researchers have discovered a new mechanism that enables plants to regulate their flowering in response to raised temperatures.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!